For men with the return of prostate cancer, a novel combined treatment can potentially give them an extended period before ...

A phase 2 trial tested the efficacy of local stereotactic body radiation therapy (SBRT) use after radical prostatectomy.

A shorter radiation course improved quality of life among men with intermediate-risk, localized prostate cancer, according to ...

Despite SBRT (radiation) to oligometastatic sites, prostate cancer progression still occurs in a majority of patients due to occult microscopic disease.

Researchers report longer progression-free survival when Lutetium-177 was combined with standard radiotherapy for limited ...

A study led by UCLA Health Jonsson Comprehensive Cancer Center investigators found that stereotactic body radiotherapy (SBRT) ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly ...

Patients with recurring prostate cancer who were treated with a new PSMA-targeted radioligand therapy before stereotactic body radiotherapy (SBRT) went more than twice as long without their disease ...

For patients with intermediate-risk, localized prostate cancer, radiation therapy delivered in five sessions reduced ...

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and ...

Primary physician reporting grade 2+ toxicity per CTCAE version 5.0 was the primary endpoint. Follow-up was performed 30 days post-treatment and subsequently every 3 to 4 months for 2 years: ...

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, announced today that its PROSTOX ultra test is now available for ordering in the United States. The ...